Clinical adverse events associated with these PI3K/AKT/mTORi such as hyperglycemia, pneumonitis, stomatitis, rashes and diarrhoea have a crucial impact on a patient’s quality of life leading to a high percentage of treatment discontinuation. This evidence concerns the gene AKT1 and pneumonitis.